entertainment -WSS

entertainment

author：focus 2025-09-06 04:39:14 - browse：8

Mayo Clinic, in Rochester, Minnesota on — Photo by KEREM YUCEL/AFP via Getty Images

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Cigna, Humana reportedly in talks to merge

WSS

STAT Summit: How researchers deal with rejection

FDA clears Verve to begin U.S. study of gene

Smaller biotechs seek to piggyback on weight loss drug boom

Organ aging and disease risk measured by new blood test

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Despite FDA concern, risk that CAR

Wikipedia

entertainment

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Despite FDA concern, risk that CAR

The high cost of giving birth even with insurance

Pediatric cancer treatments threatened by a new FDA policy

Psychedelics group wrestles with new pharma identity

FDA clears Verve to begin U.S. study of gene

Tori Bowie and the unacceptable rates of Black maternal death

BIO selects John Crowley as new CEO

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

As biotech industry slumps, bioscience job market is upside down

focus

Smaller biotechs seek to piggyback on weight loss drug boom

As biotech industry slumps, bioscience job market is upside down

Cassava Sciences’ Alzheimer’s clinical trials should be halted

ReNAgade cuts staff seven months after raising $300 million

Will the market for weight loss drugs really reach $100 billion?

STAT Summit: How researchers deal with rejection

knowledge

hotspot

hotspot

Wikipedia